Spark Therapeutics is within striking distance of a landmark green light from the FDA for its treatment for certain forms of blindness
Source: Bioethics Bulletin by the Berman Institute of Bioethics.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.